|VENTURE FUNDING TOTAL||$31M|
|Series A, 1/13 |
Labrys Biologics Inc., a company focused on treatments for chronic migraine.
Labrys Biologics has acquired worldwide rights to RN-307 from Pfizer Inc. RN-307 is an antibody for the treatment of chronic migraine.
RN-307 was originally developed by Rinat Pharmaceuticals, acquired by Pfizer in 2006.